Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
U.S. Congress
541 - 560 of 995 Results
-
-
Pharma Cash Rolls Into Congress To Defend An Embattled Industry
Congress has a variety of reforms in mind that could roil the drugmaking business and potentially slash prices.
-
KHN鈥檚 鈥榃hat The Health?鈥: All About Medicare
Before 鈥淢edicare for All,鈥 there was just Medicare, the federal program that provides insurance to 60 million Americans. This week, KHN鈥檚 Julie Rovner talks to Tricia Neuman of the Kaiser Family Foundation about how Medicare works and whom it serves. Then, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Kimberly Leonard of the Washington Examiner join Rovner to talk about some current Medicare issues being debated in Washington, D.C.
-
Health Plan鈥檚 鈥楥adillac Tax鈥 May Finally Be Running Out Of Gas
The tax on generous health plans 鈥 originally envisioned as a way to help pay for the ACA and change consumers鈥 behavior 鈥 has never been implemented, and Congress is considering repeal.
By Julie Rovner -
KHN鈥檚 鈥榃hat The Health?鈥: We Answer Your Questions
You asked about drug prices, the 鈥淐adillac tax鈥 on generous insurance plans and why Americans don鈥檛 know that most other countries also have combination public-private insurance systems. This week, Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico and Caitlin Owens of Axios join KHN鈥檚 Julie Rovner to answer those questions.
-
KHN鈥檚 鈥榃hat The Health?鈥: Gun Violence And The Politics Of Public Health
The recent tragic mass shootings have refocused efforts to treat gun violence as a public health issue rather than strictly a law enforcement problem. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Agnes Carey of Kaiser Health News join KHN鈥檚 Julie Rovner to discuss this, plus the health implications of the budget deal passed by Congress and signed by President Donald Trump, as well as reaction from Canada to a proposal to allow broader imports of its prescription drugs. Plus, for 鈥渆xtra credit,鈥 the panelists recommend their favorite health stories of the week.
-
Doctors Argue Plans To Remedy Surprise Medical Bills Will 鈥楽hred鈥 The Safety Net
A case of questionable logic.
By Rachel Bluth -
Drugmakers Master Rolling Out Their Own Generics To Stifle Competition
Known as 鈥渁uthorized generics,鈥 in-house spinoffs of brand-name drugs quietly undermine the competition.
By Jay Hancock and Sydney Lupkin -
Podcast
KHN鈥檚 鈥榃hat The Health?鈥: Deciphering The Democrats鈥 Health Debate
Health care was a major topic at the Democratic presidential candidate debates in Detroit on Tuesday and Wednesday, but the focus on plan minutiae may have left viewers more confused than edified. Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Caitlin Owens of Axios join KHN鈥檚 Julie Rovner to discuss the points made by the candidates plus a series of Trump administration health initiatives on drug prices and hospital shopping.
-
Trump Administration Moves To Make Health Care Costs More Transparent
The proposed rules would require hospitals to provide far more detail about the actual prices they charge insurers for patients鈥 care.
-
In A Messy Democratic Presidential Debate, Facts About ‘Medicare For All’ Get Tossed About
Candidates used their varying views on how to achieve universal coverage 鈥 whether through Medicare for All or more incremental steps 鈥 as a means to differentiate themselves from the field.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Klobuchar Says D.C. Has Enough Drug Lobbyists To Double-Team Lawmakers
The drug industry has the biggest lobbying war chest.
-
GOP Senators Distance Themselves From Grassley And Trump鈥檚 Efforts To Cut Drug Prices
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
-
KHN鈥檚 鈥榃hat The Health?鈥: Cue The Drug Price Debate
Democrats and Republicans on the Senate Finance Committee unveiled their long-awaited proposal to try to rein in prescription drug costs, even as bipartisan leaders of the other Senate committee that oversees health announced it would not bring its drug price bill to the Senate floor until fall. Paige Winfield Cunningham of The Washington Post, Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN鈥檚 Julie Rovner to discuss this, plus court actions on health issues.
-
Why It鈥檚 So Hard To Predict How Much Funding 9/11 First Responders Need
Eighteen years ago, most first responders were not thinking about their future health when they spent hours searching 鈥淭he Pile鈥 for the remains of terror victims. Today, their illnesses are a slow-moving epidemiological nightmare that has been as difficult for scientists to study as it has been easy for politicians to overlook.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
KHN鈥檚 鈥榃hat The Health?鈥: Biden Doubles Down On Obamacare
Presidential candidate Joe Biden unveiled a health plan intended to provide a more moderate alternative to his competitors鈥 鈥淢edicare for All鈥 plans. It would build on the Affordable Care Act but would go much further. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Kimberly Leonard of the Washington Examiner join KHN鈥檚 Julie Rovner to discuss this, plus Planned Parenthood鈥檚 very bad week, the U.S. House vote to repeal the health law鈥檚 鈥淐adillac tax鈥 on generous health plans, and the reduction in deaths from opioids.
-
Surprise Medical Bill Legislation Takes A Step Forward, But Will It Lead To A Step Back?
A House committee approved its version of legislation to solve the problem of surprise medical bills. But the measure includes a key provision that鈥檚 got less support in the Senate.
By Rachel Bluth -
A ‘No-Brainer’? Calls Grow For Medicare To Cover Anti-Rejection Drugs After Kidney Transplant
Banking on new cost estimates, a bipartisan coalition in Congress is poised to try 鈥 once again 鈥 to end a three-year limit on coverage for lifesaving medication required to keep the organs functioning.